Status:
COMPLETED
Safety and Efficacy of Edoxaban in Thoracoscopic Ablation
Lead Sponsor:
Samsung Medical Center
Conditions:
Atrial Fibrillation
Anticoagulants and Bleeding Disorders
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The aim of this study is to compare the safety and efficacy of edoxaban and warfarin for prevention of stroke during a 6-month follow up after total thoracoscopic ablation.
Detailed Description
In Korea, 5% of patients older than 65 years and 10% of patients older than 80 have a history of atrial fibrillation (AF), which is often associated with sudden death and stroke. Medication and percut...
Eligibility Criteria
Inclusion
- Patients aged 18 years or older (not exceed 80 years old).
- Elective thoracoscopic ablation.
- Presence of atrial fibrillation (paroxysmal, persistent, long-standing persistent).
Exclusion
- Chronic obstructive pulmonary disease (COPD).
- History of pulmonary tuberculosis.
- Other cardiac comorbidities including valvular disease, coronary artery disease.
- Congenital heart anomalies except for atrial septal defect.
- Known, clinically important anemia or thrombocytopenia.
- Pregnancy or lactation.
- Malignancy.
- Intracardiac mass or thrombus
- Life expectancy less than 1 year.
Key Trial Info
Start Date :
December 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 10 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04121767
Start Date
December 1 2017
End Date
July 10 2020
Last Update
August 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 135-710